istock-635475308-1-

CIPhotos / iStockphoto.com

15 February 2018Americas

BMS pays $1.85bn for immuno-oncology programme

Bristol-Myers Squibb (BMS) has agreed to pay $1.85 billion for an immuno-oncology programme.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

More on this story

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

More on this story

Roche to make $1.9bn acquisition

19 February 2018 Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.

Bristol-Myers Squibb to acquire Celgene in $74bn deal

3 January 2019 American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

BMS partners with drug accelerator to launch biotech

5 February 2020 Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York